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Abstract
Public health surveillance systems likely underestimate the true prevalence and incidence
of SARS-CoV-2 infection due to limited access to testing and the high proportion of subclini-
cal infections in community-based settings. This ongoing prospective, observational study
aimed to generate accurate estimates of the prevalence and incidence of, and risk factors
for, SARS-CoV-2 infection among residents of a central North Carolina county. From this
cohort, we collected survey data and nasal swabs every two weeks and venous blood speci-
mens every month. Nasal swabs were tested for the presence of SARS-CoV-2 virus (evi-
dence of active infection), and serum specimens for SARS-CoV-2-specific antibodies
(evidence of prior infection). As of June 23, 2021, we have enrolled a total of 153 participants
from a county with an estimated 76,285 total residents. The anticipated study duration is at
least 24 months, pending the evolution of the pandemic. Study data are being shared on a
monthly basis with North Carolina state health authorities and future analyses aim to com-
pare study data to state-wide metrics over time. Overall, the use of a probability-based sam-
pling design and a well-characterized cohort will enable collection of critical data that can be
used in planning and policy decisions for North Carolina and may be informative for other
states with similar demographic characteristics.
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Introduction
In addition to the direct health impacts, the COVID-19 pandemic has caused unprecedented
levels of disruption to the global economy and civil society. While critical to limiting disease
transmission and associated morbidity and mortality, prevention measures have taken a signif-
icant toll [1, 2]. Nearly every aspect of daily life, including business, education, organized reli-
gion, and social activities, has experienced restrictions and temporary closures as a result of
the pandemic.
Decisions regarding how and when to scale back such restrictions are complex. Premature
easing may result in a rebound of cases [1] even in the presence of vaccines [3, 4], while
extending restrictions may inflict irreversible damage to the economy and to children’s health
and development [5, 6], especially in already distressed rural communities. Until vaccination
rates or “natural immunity” from exposure reach critical thresholds, guidance on the scope
and duration of restrictions will continue to require epidemiological measurements of com-
munity infections.
Current estimates of SARS-CoV-2 incidence, prevalence across geographic regions, and
mortality rates are largely drawn from seroprevalence studies [7], which measure antibod-
ies against the virus found in blood samples. These studies vary by design, serological test
employed, and statistical methods. In addition, a large proportion of studies to date have
used convenience samples that may reflect very different populations and are subject to a
number of biases, foremost of which is related to the selection of participants. Yet the
results of these studies are frequently extrapolated to the general population and are inter-
preted interchangeably, despite not reflecting the underlying population in demographic
composition and risk factors for COVID-19 infection, leading to estimates of questionable
accuracy [8].
The seroprevalence of SARS-CoV-2 is rapidly changing in North Carolina [9], a state with
fast-growing urban centers interspersed among the second-largest rural population in the
country. Limited studies have been conducted among frontline health care workers [10] and
among those seeking healthcare unrelated to COVID-19 [11]. However, no studies to date
have used representative population estimation methods and often rely on convenience sam-
pling, which is difficult to extrapolate to underlying populations [7]. Therefore, there is an
urgent need to conduct prospective, population-based surveillance to define the epidemiologic
curve and provide accurate and timely information to policymakers. This need is particularly
acute as the Centers for Disease Control and Prevention (CDC) estimates that up to 70% of
individuals infected with SARS-CoV-2 are asymptomatic [12], and others experience only
mild symptoms that do not prompt care seeking and diagnostic testing [13, 14]. As the pan-
demic evolves and vaccination efforts expand in North Carolina [15], such surveillance also
enables estimates of vaccine intention and uptake.
Here, we describe the protocol of an ongoing study that was designed to estimate and exam-
ine a truer population-based incidence and prevalence of SARS-CoV-2 infection in a represen-
tative sample of adults residing in one county in central North Carolina. We hypothesized that
a population-based community incidence and prevalence estimate would be substantially
higher than estimates derived from facility-based samples, largely due to limited access to test-
ing during the early phase of the pandemic and the high proportion of infections that are
asymptomatic or mild, and thus do not prompt care seeking. This observational study also
sought to identify demographic, socioeconomic, and geographic risk factors for SARS-CoV-2
infection, and to characterize self-reported symptoms, health-seeking behaviors, and clinical
outcomes in relationship to seroprevalence results.
PLOS ONE SARS-CoV-2 infection in central North Carolina
PLOS ONE | https://doi.org/10.1371/journal.pone.0259070 October 25, 2021 2 / 13
and Human Services, Division of Public Health
(https://publichealth.nc.gov/), contract 00041877
awarded to author RB. The funders did not have
and will not have a role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Materials and methods
Study overview
We conducted a prospective, observational study of SARS-CoV-2 among residents of Chatham
County, North Carolina (S1 Fig). Chatham County was selected as the setting because it has many
characteristics that make it broadly representative of the state of North Carolina, including distinct
semi-urban and rural areas and a diverse mix of residents both in terms of demographics and
socioeconomic status (see S1 Table). The county was affected by high-profile outbreaks at nursing
homes as well as poultry processing plants, which have disproportionately impacted Hispanics/
Latinos and other historically marginalized communities [1]. Based on precision-based sample
size calculations made early in the course of the pandemic, we aimed to enroll up to 300 partici-
pants. Eligibility criteria included current residence in Chatham County, age of 18 years or older,
and willingness and ability to provide informed consent. As described in detail below, study par-
ticipants were regularly surveyed on their demographic characteristics, occupation, infection pre-
vention activities and behaviors, illnesses and health, and psychosocial health. Survey data on the
health of their household members was also collected. Venous blood was collected from partici-
pants on a monthly basis, and nasal swabs were self-collected on a bi-weekly basis (Fig 1).
Ethical considerations
Study protocols were reviewed by the University of North Carolina at Chapel Hill Institu-
tional Review Board. Initial approval (Study #20–1632) was granted under expedited review
Fig 1. Overview of study timeline. Created with BioRender.com.
https://doi.org/10.1371/journal.pone.0259070.g001
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under 45 CFE 46.110 on June 10, 2020. Written informed consent was obtained from all
participants.
Recruitment
Initial study recruitment leveraged and expanded upon the Chatham County Community
Cohort, which was established by the Chatham County Health Department during their 2018
Community Assessment to track the health status of a representative sample of residents over
time [16]. Investigators met with the Chatham County Community Assessment Scientific
Advisory Committee on April 9, 2020 to describe the study objectives and methods. Ample
time was provided for committee members to ask questions and provide feedback, which was
incorporated into the proposal.
To raise community awareness of the study, we collaborated with the Office of Rural Initia-
tives at the University of North Carolina at Chapel Hill (UNC). Informational flyers were handed
out at food distribution sites and other community events in August and September 2020 and at
mobile markets (drive-thru food distribution sites) in November and December 2020.
Recruitment efforts sought to enroll one person per sampled household. Participants were
selected in two different phases. Phase One was recruited from the existing, population-based
Chatham County Community Cohort. Residents of Chatham County were sampled for the
Chatham County Community Cohort via a stratified two-stage cluster design. Census blocks
were stratified into three income tertiles and 21 census blocks were selected per stratum using
probability proportional to size with replacement (PPS-WR) sampling with the estimated
number of occupied households in each census block serving as the measure of size. Income
tertiles used the 33rd and 66th percentiles, so that income ranges used were:<$47,000; $47,000
- $58,000; and>$58,000. Within each selected census block, seven households were selected
for inclusion in the Chatham County Community Cohort using a modified Community
Assessment for Public Health Emergency Response (CASPER) sampling methodology [17].
Community Cohort participants who responded to a questionnaire given as part of the 2020
Chatham County Community Health Assessment via email or phone were offered the oppor-
tunity to participate in our study.
Phase One recruitment included contacting potential participants from the Chatham
County Community Cohort via email and telephone, with up to three emails per email address
and up to five telephone attempts per phone number. Recruitment among the 189 cohort
members who responded to the 2020 questionnaire (Phase One) was not expected to yield the
targeted number of participants for the study. Therefore, further recruitment was conducted
within an additional sample of households, herein Phase Two. Our Phase Two design used the
same sampling approach for selecting census blocks as the Chatham County Community
Cohort, enabling us to combine samples from both phases. Namely, a stratified PPS-WR sam-
ple of 99 census blocks was selected for Phase Two. Address-based sampling frames were com-
piled for the selection of households from within the chosen census blocks [18], with inclusion
of addresses from the supplemental No-Stat file to maximize sample representation in rural
areas [19]. Within-block sample sizes were derived based on the demographics of selected
blocks, with oversampling of addresses within census blocks with higher concentrations of
Hispanic/Latino and/or Black/African American populations. This led to an overall supple-
mental sample of 1,402 addresses from 80 unique census blocks. Assuming a household occu-
pancy rate of 90% and a response rate of 20%, the combined Phase One and Phase Two
samples were anticipated to yield approximately 300 study participants.
Phase Two recruitment involved sending a postcard (S1 Fig) to households in our sample
to provide information regarding the study and encourage enrollment. Postcards were sent up
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to three times per address and referenced a study-specific website where members of sampled
households could learn more about the study and submit an online pre-screening survey con-
veying their desire to be contacted for participation. Phone numbers were available for approx-
imately 76% of the Phase Two addresses. As in Phase One, sampled households with available
phone numbers in Phase Two were contacted by telephone up to five times. Study team mem-
bers made in-person visits to selected Phase Two households that were not reachable by tele-
phone and had not responded to postcards, beginning in February 2021. Staff wore
identification and personal protective equipment and maintained at least six feet of distance
from household members during visits. If there was no response, a flyer containing contact
information for the study was left at the front door (See S2 Fig).
Consent and enrollment
If a member of a household sampled in either Phase One or Phase Two expressed an interest
in participation, staff conducted a verbal consent process with an electronic consent form
using the AdobeSign program. A copy of the signed consent form was then provided to the
participant by email. For participants lacking access to email, verbal consent was obtained over
the phone then confirmed in writing at the participant’s first in-person study visit.
Once enrolled, each participant was assigned a unique study ID for linkage of data sources.
Questionnaire and surveys
Baseline. After enrollment, participants received an electronic questionnaire regarding
their demographic characteristics, occupations, infection prevention practices, health history,
current COVID-19 symptoms, and personal and professional impacts of the COVID-19 pan-
demic (S1 Appendix). All surveys were available in English and Spanish. This initial question-
naire also inquired about the participant’s household (i.e., number of people, occupations, and
current infection symptoms) and included basic mental health assessments for depression and
anxiety [20, 21].
Biweekly. Participants received a shorter survey by email every two weeks to gather data
on current occupational status, current infection prevention practices, personal and profes-
sional impacts of the COVID-19 pandemic, and symptoms experienced during the previous
two weeks (S2 Appendix). The biweekly survey was also designed to collect information on
household members, including current occupational status and symptoms experienced during
the previous two weeks. In December 2020, the first COVID-19 vaccines were approved by the
U.S. Food and Drug Administration and became available to the state of North Carolina [15].
To capture subsequent vaccination trends among participants, surveys were updated on
March 11, 2021 with questions on when and if participants had received one or both vaccine
doses, intention to vaccinate when available, and type of vaccine received.
Specimen collection
Participants were given the option to provide specimens during monthly study visits with at-
home specimen collection between visits or, if unable to attend study visits due to lack of trans-
portation or other barriers, to contribute specimens entirely from home via self-collection (See
Fig 2).
Study visits. Study visits occurred at one of two clinic sites in Chatham County. Partici-
pants attended monthly clinic visits for venous phlebotomy and collection of mid-turbinate
nasal swabs (MTNS). Routine vital signs, including height and weight, temperature, pulse, and
oxygen saturation by pulse oximetry, were measured and recorded at each visit. At the conclu-
sion of each visit, participants took home an MTNS kit for self-collection of a specimen at the
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biweekly interval between monthly in-person visits. Participants were asked to refrigerate the
nasal specimen until it could be brought to their subsequent monthly visit.
Baseline visit. For participants’ first study visit, the take-home kit for the MTNS also
included a digital thermometer. Participants were instructed to begin taking their oral temper-
ature daily if they developed symptoms consistent with SARS-CoV-2, defined as cough, fever
or chills, difficulty breathing, fatigue, body aches, diarrhea, and loss of taste or smell [22].
Mid-Turbinate Nasal Swab (MTNS) collection. Participants were given a nasal swab
self-collection kit containing an instruction card and were also verbally instructed on usage.
Participants were asked to tilt their head back at a 70-degree angle and insert the mid-turbinate
swab into their right nostril until the entire tip of the swab entered the nose and resistance was
felt at the turbinate. Participants then rotated the swab three times against the nasal wall and
held it in place for 5 seconds. The process was repeated with the left nostril. Upon removal, the
swab specimen was placed into a vial containing DNA/RNA Shield medium (Zymo Research,
Irvine, CA). Vials were placed into biohazard bags and refrigerated immediately after
collection.
Venous phlebotomy. At participants’ monthly clinic visits, trained phlebotomists col-
lected two cell preparation tubes (CPT tubes) containing up to 20 ml(cm3) of venous blood in
each tube (BD Vacutainer Mononuclear Cell Preparation Tube (CPT)—Sodium Citrate, BD
Biosciences, San Jose, CA).
Tasso at-home collection. If participants opted for at-home collection only, they were
mailed a self-collection kit each month consisting of a Tasso serum self-collection device
(Tasso, Inc., Seattle, WA) to collect a monthly blood specimen and MTNS supplies to collect
Fig 2. Participant enrollment and study procedures.
https://doi.org/10.1371/journal.pone.0259070.g002
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nasal specimens every other week. For blood specimen collection, participants were instructed
to wash hands and sterilize skin with an alcohol wipe. The Tasso device was adhered to skin to
collect the specimen for 5 minutes, then removed. The device was then sealed into a provided
biohazard bag, placed in return packaging, and shipped back to study staff for processing,
along with nasal specimens.
The collection, processing, and storage of specimens followed national and international
guidelines, and all processes were approved by Environmental Health Services at UNC. For
full laboratory protocol, please see S3 Appendix.
Specimen testing
Enzyme-Linked Immunosorbent Assay (ELISA) and Abbott architect for SARS-CoV-2
antibodies. CPT tubes were processed for plasma up to 16 hours after collection, but typically
within 8 hours of collection. Plasma collected from participants at in-person study visits and
serum self-collected by participants via Tasso devices were both tested via ELISA, using the
receptor binding domain (RBD) of the SARS-CoV-2 spike protein to detect total SARS-CoV-2
immunoglobulin (Ig) in plasma [23]. Specimens were also tested via the Abbott Architect
Immunoassay, using the nucleocapsid protein to detect total SARS-CoV-2 IgG in plasma [24].
Peripheral Blood Mononuclear Cell (PBMC) isolation. CPT tubes were further pro-
cessed for PBMC collection if collected during a participant’s baseline, 6-month, or 12-month
study visit (See S3 Appendix) [25]. PBMCs were stored in aliquots of 3–6 million cells/μL
(cells/mm3) at -80˚C (193.15 K) for testing or –140˚C (133.15 K) for long-term storage and
future research.
Mid-Turbinate Nasal Swabs (MTNS). Following collection, MTNS were preserved in a
DNA/RNA Shield medium that inactivates all infectious pathogens. MTNS collected during
clinic visits were sent to the North Carolina State Laboratory for Public Health for detection of
SARS-CoV-2 virus using the CDC Influenza SARS-CoV-2 (Flu SC2) multiplex polymerase
chain reaction (PCR) assay [26]. MTNS collected at home by participants between clinic visits
were stored at –20˚C (253.15 K) upon receipt by study staff. Using a Qiagen Viral RNA Mini
Kit [27], RNA was extracted from 200μl(mm3) of the DNA/RNA shield, then processed for
SARS-CoV-2 PCR testing using the TaqPath™ COVID-19 Combo Kit [28].
Data analysis
All data were stored in a HIPAA-compliant database using REDCap [29].
Outcomes. Our primary outcomes of interest were the monthly incidence and cumulative
prevalence of SARS-CoV-2 infection, defined as either development of SARS-CoV-2-specific
antibodies as determined by ELISA (i.e., seroconversion) or clinical infection with SARS-CoV-
2 confirmed by PCR testing. Secondary outcomes of interest included: (1) demographic factors
(age, occupation, gender, household context, etc.), occupational factors (specific occupation,
occupational exposures), and self-reported preventive behaviors (e.g. mask use, handwashing,
etc.) associated with relative risk of SARS-CoV-2 infection; (2) proportion of confirmed infec-
tions that are sub-clinical and/or asymptomatic; (3) SARS-CoV-2 vaccination status or intent
to vaccinate; and (4) agreement between serological testing results obtained from venous
blood collection and Tasso device. Exploratory outcomes included genotypic analyses of the
SARS-CoV-2 viral isolates.
Sample size. A simulation study was conducted to empirically estimate the anticipated
precision of the estimated prevalence of seroconversion during the study period, accounting
for the study design. Data available at the time of study design suggested an infection preva-
lence of 5% [30]. Assuming 5% of individuals would seroconvert during the study period and
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assuming correlation in infection prevalence within clusters, we estimated that the 95% confi-
dence interval for the seroconversion estimate would have a half-width of approximately 3%
based on a sample size of 300 participants.
Proposed statistical analyses. Sampling weights will be calculated for each participant.
To account for differential nonparticipation with respect to calibration variables, base weights
accounting for each household’s probability of study selection will be calibrated to general
Chatham County population totals derived from the American Community Survey using gen-
eralized exponential modeling [31, 32]. Calibration variables will include sampling stratum,
sex, age, race/ethnicity, educational attainment, household size, and geographic region. The
weighted sample is expected to be representative of adult Chatham County residents with
respect to these measured calibration variables.
Weighted cross-sectional means, proportions, and categorical distributions will be esti-
mated for survey and clinical outcomes along with accompanying standard errors and 95%
confidence intervals. Specifically, monthly incidence rates and cumulative prevalence of
COVID-19 will be estimated. Longitudinal models will be used to estimate changes in infec-
tion and prevalence rates over time, using generalized estimating equations with robust vari-
ance estimation to account for correlation within individuals over time and correlation within
clusters. From these models, we will also evaluate demographic, socioeconomic, and geo-
graphic risk factors for COVID-19 infection.
Our longitudinal study design incorporating prospective sero-surveillance will facilitate the
identification of risk factors for asymptomatic and mild cases of COVID-19 in addition to risk
factors for symptomatic cases. In addition, the prospective study design will allow assessment
of vaccination uptake and calculation of herd immunity estimates. All analyses will appropri-
ately account for the complex multi-stage sample design, including weighting, stratification,
and clustering with use of survey analysis software (e.g., using the R “Survey” package, SAS’
survey procedures, and SUDAAN). We will also examine the spatio-temporal patterns of
COVID-19 positive cases at the block group level to understand the neighborhood effects and
rural-urban gradient of COVID-19 risk.
To validate serological results obtained using the Tasso at-home collection device, we will
assess for concordance between ELISA antibody testing results from specimens collected by the
Tasso device as compared to venous phlebotomy, which is considered the standard specimen col-
lection procedure, through calculation of Cohen’s kappa coefficient. The test performance of our
ELISA antibody assay targeting the RBD protein antigen will be compared to the Abbott Archi-
tect Immunoassay for SARS-CoV-2 IgG, targeting the nucleocapsid antigen [24, 33]. In conjunc-
tion with survey-collected data on vaccination status, comparing serological assays with differing
antigen targets will allow for distinction between natural immunity from SARS-CoV-2 infection
and acquired immunity from vaccination and allow us to characterize and compare the resulting
immune responses based on one of eight possible diagnostic combinations (Table 1).
Results
Recruitment for this study began on August 20, 2020 and is ongoing, with enrollment antici-
pated to continue through July 2021. Of the 1536 eligible households sampled in Phases 1 and 2,
we have received a response from 608 households (39.6%) thus far. Of these 608 households,
379 have opted out (62.3%). As of June 23, 2021, 153 participants from 152 households have
been enrolled, including one participant who withdrew from the study due to moving out of the
area and was subsequently replaced by another household member. Of the 153 participants who
have been enrolled to date, 53 (34.6%) were enrolled from the Phase One sample and 99
(64.7%) were enrolled from the Phase Two sample. One participant not included in either
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sample was also inadvertently enrolled. The majority of samples collected have successfully
been analyzed; 0.8% (9 out of 1069) of nasal swabs collected for PCR testing by the North Caro-
lina State Lab of Public Health were unusable due to shipping delays, damage to the materials,
or not enough sample collected. 16.5% (20 out of 121) of samples from Tasso devices were not
usable due to participant error or too small of volume of blood collected, or other causes.
Discussion
Our study design has several unique and novel aspects that maximize its potential for far-
reaching impact. Foremost among these is the probability-based sampling design, which
enables us to obtain a more complete picture of how and why SARS-CoV-2 may be spreading
throughout rural, under-resourced communities. This sampling design helps to ensure that
the estimates generated are generalizable to the household population in Chatham County,
which is demographically similar to the state of North Carolina (S1 Table). As a result, this
data can be used to inform planning and policy decisions that benefit the state as a whole.
Another advantage of our approach is the inclusion of lower-income communities and
rural areas, which, despite the initial focus on urban areas, have been particularly stricken by
the COVID-19 pandemic in North Carolina [34]. Approximately 40 percent of North Caroli-
na’s population resides in rural communities like Chatham County [35]. Rural communities
often have fewer clinics and hospitals, and therefore less access to testing and treatment. Rely-
ing exclusively on positive tests and hospital admissions has the potential to miss a substantial
proportion of infections in these communities. In addition, rural communities host major
agricultural production facilities with many workers deemed “essential” [36]. Such facilities
have been particularly hard hit by outbreaks of SARS-CoV-2 infection [1]. Conducting our
study within a county that hosts multiple meat-processing plants gives us the opportunity to
study how agricultural facilities affect community transmission of SARS-CoV-2.
Our study cohort is also exceptionally well-characterized for multiple reasons: 1) building
our cohort on a pre-existing population-based cohort expedited enrollment and data collec-
tion early in the pandemic, enabling us to collect data from the same individuals over an
extended period of time and 2) collecting information of substantial depth and breadth regard-
ing participants’ clinical symptoms of and occupational exposures to SARS-CoV-2, infection
prevention behaviors, mental health, and perceptions of the epidemic through repeated elec-
tronic questionnaires. The timing and frequency of survey data collection allows us to examine
shifts in participants’ beliefs and behaviors before SARS-CoV-2 vaccines were available, during
vaccine roll-out, and after widespread vaccination. Due to the demographic similarity of Chat-
ham County to the state of North Carolina, this information can inform vaccine planning
Table 1. Distinction between natural immunity from SARS-CoV-2 infection and acquired immunity from vaccination, based on vaccination status, ELISA RBD
antibody assay, and Abbott architect SARS-CoV-2 IgG assay targeting the nucleocapsid protein.
Possible
combination





1 Yes Yes Yes Past infection and vaccinated
2 Yes No No Likely past infection and not
vaccinated3 Yes Yes No
4 No Yes No
5 No Yes Yes Vaccinated/uncertain immune
response6 No No Yes
7 Yes No Yes Vaccinated but no past infection
8 No No No
https://doi.org/10.1371/journal.pone.0259070.t001
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efforts at the community and state levels. The frequency of specimen collection also allows us
to quickly detect emerging trends, including surges in infections, vaccination uptake, and vac-
cine effectiveness.
While our approach has many strengths, it also has some limitations. Due to differential
rates of participation, our cohort may overrepresent older age groups and persons more likely
to be at home during the pandemic. It may also underestimate those with pre-existing condi-
tions or other high-risk individuals due to a reluctance to attend in-person clinic visits. Further-
more, our sampling frame does not cover institutionalized individuals, including persons
residing in nursing homes and individuals who are incarcerated. We attempted to minimize
potential biases by offering at-home collection kits, implementing multiple modes of recruit-
ment over the span of several months, including home visits, telephone calls, and electronic and
postal mailings, and using weight calibration adjustments during analysis to incorporate factors
associated with study participation. In addition to minimizing potential biases, our adaptive
approach to specimen collection has the advantage of being able to capture specimens from par-
ticipants with active infections who otherwise would have been restricted from attending clinic
visits in person. However, despite the opportunity to conduct at-home specimen collection as
needed, our sampling strategy may not capture all incident infections occurring between nasal
swab collections because of the relatively short duration of detectable viral shedding. Finally,
our study will identify asymptomatic and undetected infections through monthly serological
testing, although this could create more variability in estimates of infection onset.
Conclusions
This article describes the protocol for a prospective, longitudinal, population-based cohort study
that will generate crucial data about the prevalence and incidence of SARS-CoV-2 infection,
trends in SARS-CoV-2 infection over time, vaccination uptake, and risk factors for SARS-CoV-2
infection within a semi-urban and rural county in North Carolina, with broad application for
informing state public health policy. This study design is adaptable to different regional settings,
and therefore can be duplicated to provide epidemiological knowledge across a larger geographic
area. We know of two other groups that have modeled their studies after ours thus far, covering
the areas of Pitt County in eastern North Carolina (https://compactstudy.ecu.edu/) and Cabarrus
County in south-central North Carolina (https://murdock-study.com/ongoing-studies/mur
dock-cabarrus-county-covid-19-prevalence-and-immunity-study/), and we have shared study
protocols, best practices, and our surveys with these groups. Such collaborative research net-
works provide opportunities to aggregate data for comparison and offer surveillance infrastruc-
ture urgently needed for future pandemic preparedness.
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